Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
All-cause mortality [ Time Frame: Change from Baseline at 3, 6 and 12 months ]
Secondary Outcome Measures :
New York Heart Association (NYHA) Classification [ Time Frame: Week:4 ]
re-hospitalization [ Time Frame: Change from Baseline at 3, 6 and 12 months ]
Heart failure with re-hospitalization is documented by at least one of the following: worse exercise tolerance and respiratory distress with NYHA class III or IV symptoms, presence of pulmonary rales, or chest radiography showing pulmonary congestion, which needs an augmented decongestive regimen with oral or intravenous medications during an in-hospital stay.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years to 80 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients With Chronic Heart Failure
Patients who are giving open chest surgical treatment with a history of chronic heart failure (NYHA II ~ IV) more than 6 months.
Patients from whom informed consent has been properly obtained in writing prior to start of the trial.
Patients with concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases,or any other malignancy.
Patients with a history of cardiomyopathy.
Patients with Chronic arrhythmia.
Severe hepatic dysfunction or End-stage renal failure.